Loading
Life sciences · Journal article
Oncologie · September 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Abstract Cancer immunotherapy, particularly immune checkpoint inhibitors (ICIs) and chimeric antigen receptor T-cell (CAR-T) therapy, has transformed the treatment landscape of multiple malignancies. However, dysregulated immune activation can cause a wide range of toxicities that may disrupt treatment, impair long-term health, and reduce quality of life. This review summarizes the clinical manifestations, underlying mechanisms, long-term consequences, and management of toxicities associated with ICIs and CAR-T-cell therapy. It covers immune-related adverse events induced by ICIs; cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, which occur predominantly after CAR-T-cell therapy; and hematologic and organ-specific toxicities affecting the skin, gastrointestinal tract, liver, lungs, heart, kidneys, endocrine organs, and nervous system. Late-onset and persistent complications, including fatigue, endocrine dysfunction, gastrointestinal disorders, neurological impairment, and psychological distress, are also discussed. These toxicities may result from excessive immune activation, loss of immune tolerance, cytokine dysregulation, alterations in the tumor microenvironment, treatment interactions, and individual susceptibility. Early recognition, close monitoring, standardized toxicity grading, and individualized management are essential to minimize severe complications while preserving antitumor efficacy. Future studies should focus on identifying reliable predictive biomarkers and developing risk-stratification models to improve the safety and personalization of cancer immunotherapy.